PARP1 and ovarian carcinoma: More targeted therapies including vascular endothelial growth factor A (VEGF‐A) inhibitors and poly ADP-ribose polymerase (PARP) inhibitors have become new therapeutic options in managing ovarian cancer (6, 7).